Benefits of Allergy Shots: Four Evidence-Based Outcomes
The four documented benefits of subcutaneous immunotherapy are: symptom reduction (Cochrane symptom SMD −0.73, Calderón 2007, 51 RCTs / 2,871 patients), medication reduction (~80% in grass SCIT, Walker 2001), pediatric asthma prevention (OR 4.6 at 10-year follow-up, Jacobsen 2007), and durable post-treatment remission (≥3 years after stopping, Durham 1999). All four are evidence-grade — not anecdote. Honest caveats: only 43.9% of US starters reach maintenance (Tkacz 2021).
8 peer-reviewed sources
Allergy shots provide four documented benefits: symptom reduction (SMD −0.73), medication reduction (~80% for grass), durable post-treatment remission (≥3 years), and asthma prevention in children (OR 4.6 at 10 years). No other allergy treatment produces post-treatment benefit.
The essentials
Subcutaneous immunotherapy (SCIT) offers four documented clinical benefits that distinguish it from every other allergy treatment. Understanding each benefit — and what the actual evidence says — helps patients and clinicians make realistic, evidence-grounded decisions about whether to pursue a 3–5 year treatment course.
Benefit 1 — Symptom reduction. The Cochrane meta-analysis by Calderón MA et al. (2007, CD001936, DOI 10.1002/14651858.CD001936.pub2) synthesized 51 double-blind, placebo-controlled RCTs involving 2,871 patients and found a pooled symptom SMD of −0.73 (95% CI −0.97 to −0.50). This is a moderate-to-large effect in clinical research, equivalent in magnitude to intranasal corticosteroids. For venom allergy, the benefit is more dramatic: Boyle RJ et al. (Cochrane 2012, PMID 23076950) found subsequent systemic sting reactions in only 2.7% of treated patients versus 39.8% of untreated controls (RR 0.10).
Benefit 2 — Medication reduction. The same Cochrane meta-analysis found a medication SMD of −0.57 (95% CI −0.82 to −0.33). In practice, grass SCIT produced approximately 80% medication-score reduction versus placebo at P=.007 in Walker SM et al. (JACI 2001;107:87–93, DOI 10.1067/mai.2001.112027). For asthma, Abramson MJ et al. (Cochrane 2010, CD001186) found an NNT of 3 to prevent one patient's asthma deterioration across 88 SCIT trials.
Benefit 3 — Pediatric asthma prevention. Jacobsen L et al. (Allergy 2007;62:943–948, DOI 10.1111/j.1398-9995.2007.01451.x) followed children who had received a 3-year course of grass/birch SCIT. At 10-year follow-up, only 25% of treated children had developed asthma versus 45% of controls — an adjusted OR of 4.6 (95% CI 1.5–13.7) for remaining asthma-free. The preventive effect persisted approximately 7 years after treatment ended. The 5-year data (Niggemann B et al., Allergy 2006;61:855–859) confirmed intermediate persistence.
Benefit 4 — Durable post-treatment remission. Durham SR et al. (NEJM 1999;341:468–475, DOI 10.1056/NEJM199908123410702) randomized patients who had completed 3–4 years of grass SCIT to continue or discontinue; the discontinuation group maintained clinical remission comparable to continued treatment for at least 3 further years, with persistent immunologic changes. This post-treatment durability — absent from every pharmacotherapy — is the defining benefit of immunotherapy as a disease-modifying treatment.
Curex at-home IgE testing with allergist review identifies which specific allergen drives a patient's symptoms — necessary because the benefit-magnitudes documented in Cochrane and PAT-study evidence assume the extract matches the dominant sensitization, not a generic multi-allergen mix.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Efficacy by allergen — what the data shows
Each of the four benefits is documented across specific allergens with specific primary sources. The per-allergen evidence base varies — venom and grass have the strongest data; mountain cedar and non-Alternaria molds have the thinnest.
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youTreatment options side by side
Pharmacotherapy and avoidance offer symptomatic benefit but no post-treatment durability. Only immunotherapy (SCIT or SLIT) is disease-modifying — changing the underlying sensitization rather than masking downstream symptoms.
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
SCIT (allergy shots) | |||||
SLIT drops (off-label) | |||||
Pharmacotherapy alone |
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
For patients who want these disease-modifying benefits without the 3-5 year weekly-clinic burden, Curex delivers the allergy shot itself at home for $129/month. The personalized serum is sterile-compounded to USP <797>, a prescribed epinephrine auto-injector is confirmed on hand before the first dose, and a board-certified allergist supervises your first injection and every dose change live over Zoom — so eligible patients capture the same four documented benefits with one weekly shot at home.
See if at-home shots are right for youFrequently asked questions
What are the main benefits of allergy shots?
The four documented benefits are: (1) symptom reduction — Cochrane symptom SMD −0.73 across 51 RCTs and 2,871 patients (Calderón 2007); (2) medication reduction — Cochrane medication SMD −0.57, with approximately 80% medication-score reduction in grass SCIT (Walker 2001); (3) pediatric asthma prevention — adjusted OR 4.6 for remaining asthma-free at 10-year follow-up after 3 years of pediatric SCIT (Jacobsen 2007); and (4) durable post-treatment remission — clinical remission sustained at least 3 years after stopping a 3–4 year course (Durham 1999). A fifth, quality-of-life benefit is measurable on the RQLQ instrument (Walker 2001 median between-group difference 0.8 during pollen season). All four benefits require completing the full 3–5 year course per Cox 2011 PP3.
Do allergy shots provide lasting benefit after stopping?
Yes — post-treatment durability is SCIT's unique advantage over pharmacotherapy. Durham SR et al. (NEJM 1999;341:468–475) randomized patients who had completed 3–4 years of grass SCIT to either continue or stop; the discontinuation group maintained clinical remission comparable to the continuation group for at least 3 further years, with persistent immunologic changes (elevated IgG4, inverted IgE/IgG4 ratio). Cox and Cohn (Ann Allergy Asthma Immunol 2007, PMID 17521025) reviewed post-treatment relapse across studies and found relapse rates ranging from 0% to 55%, with lower rates for grass pollen and higher rates (up to 55%) for dust mite — which is why the decision to stop immunotherapy is individualized by allergen. No antihistamine or intranasal corticosteroid provides post-treatment benefit.
Can allergy shots prevent my child from developing asthma?
The PAT (Preventive Allergy Treatment) study provides compelling evidence for this benefit. Jacobsen L et al. (Allergy 2007;62:943–948) followed children who had received 3 years of grass/birch SCIT and found at 10-year follow-up that the treated group had an adjusted OR of 4.6 (95% CI 1.5–13.7) for remaining asthma-free compared to controls — meaning treated children were 4.6 times more likely to not have developed asthma. The preventive effect persisted approximately 7 years after treatment ended. Niggemann B et al. (Allergy 2006;61:855–859) confirmed the 5-year intermediate data. This is a European RCT (grass and birch allergens); applicability to US-specific allergen profiles like ragweed should be considered when making individual decisions.
Do allergy shots reduce the need for daily medications?
Reducing or eliminating daily allergy medications is one of SCIT's most clinically meaningful benefits. The Calderón 2007 Cochrane meta-analysis found a medication SMD of −0.57 across 51 RCTs — meaning patients on active SCIT used significantly less rescue medication than placebo. In grass SCIT, Walker SM et al. (JACI 2001) specifically documented approximately 80% medication-score reduction versus placebo (P=.007). In practice, many patients reduce or stop daily antihistamines and intranasal corticosteroids during years 2–3 of maintenance. This reduction persists after completing the course (Durham 1999), meaning the ongoing medication cost and inconvenience are reduced even after the immunotherapy course ends.
How does venom allergy benefit from allergy shots?
Hymenoptera venom immunotherapy (VIT) is the most effective form of immunotherapy in clinical medicine. Boyle RJ et al. (Cochrane 2012, PMID 23076950) found subsequent systemic sting reactions in 2.7% of VIT-treated patients versus 39.8% of untreated controls — a risk ratio of 0.10 (95% CI 0.03–0.28). Golden DBK et al. (JACI 2005;115:439–447) states VIT prevents systemic reactions in more than 95% of treated patients, with single-vespid VIT 85–90% effective and honeybee VIT 75–85% effective. Protection commonly persists after stopping a 3–5 year course. For patients with venom allergy, the alternative is potentially fatal anaphylaxis — making the benefit-risk calculation strongly favorable for VIT. Patients are still advised to carry an epinephrine auto-injector even after completing treatment.
What is the quality-of-life benefit of allergy shots?
Beyond symptom and medication scores, allergy shots produce measurable quality-of-life improvement on the validated Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ, Juniper 1991). Walker SM et al. (JACI 2001;107:87–93) found grass SCIT produced a median between-group RQLQ difference of 0.8 (95% CI 0.18–1.5) during pollen season — above the conventional 0.5 within-patient minimal important difference. The between-group MID in AIT trials is smaller (0.10–0.26 for grass and tree allergens per Blaiss M et al., Allergy 2022;77:1843–1851, DOI 10.1111/all.15207), meaning population-level benefits are real but vary. Modern regulatory trials now use composite endpoints — Total Symptom Score, Total Medication Score, and Combined Symptom-Medication Score (EMA/EAACI preferred) — that capture both symptom and medication dimensions of quality of life.
Are allergy shot benefits worth the time investment?
For most patients with moderate-to-severe allergy who can sustain the course, the evidence supports a favorable benefit-to-burden ratio. The Hankin CS et al. (JACI 2013;131:1084–1091, DOI 10.1016/j.jaci.2012.12.662) Florida Medicaid analysis found SCIT was associated with significantly reduced total healthcare costs versus matched controls. The durability multiplier is key: ≥3 years of post-treatment benefit (Durham 1999) and potentially 7–12 years in some cohorts means the time investment of a 3–5 year course pays dividends for many years after completion. The honest caveat is that the benefits are only realized by the 43.9% who reach maintenance (Tkacz 2021, n=103,207 MarketScan). The 3–5 year commitment, ~39 Year-1 clinic visits, 30-minute observation per visit, and 0.1% systemic-reaction rate per visit are the costs against which these benefits must be weighed.
Related Articles
Allergy Shot Effectiveness Per Injection | Curex Guide
No single allergy shot is effective alone. Build-up takes 26–28 weekly shots. Most patients notice improvement at months 6–12. Cochrane cumulative SMD −0.73 after 3–5 years.
Read moreAllergy Treatment Choices Compared | Curex Guide
Four evidence-based allergy treatment options: pharmacotherapy, SCIT (SMD −0.73), immunotherapy, and avoidance. Cochrane data, 3–5 yr commitment, honest pros and cons.
Read moreCat Allergy Vaccine Explained | Curex SCIT Guide
Cat allergy vaccine means three different things. SCIT uses FDA-standardized Fel d 1 extract for ~72% symptom relief. No one-shot cure exists.
Read moreIs Allergy Shots Worth It? 6 Questions Answered
Are allergy shots worth it? Six honest questions — efficacy, duration, visits, dropout, cost, and durability — answered with Cochrane and Tkacz data.
Read moreAllergy Therapy: All Treatments Explained | Curex
Allergy therapy spans pharmacotherapy, SCIT shots, SLIT drops, and biologics. Only SCIT and SLIT modify the underlying disease. Learn which therapy fits your situation.
Read moreDo Allergy Shots Work? Evidence & Honest Verdict | Curex
Do allergy shots work? Meta-analyses of 51 RCTs show 33-85% symptom reduction — but 20-50% of patients are low responders. Here's the honest evidence.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.